Nephros Company Top Insiders
| NEPH Stock | USD 2.19 0.05 2.34% |
Nephros' insiders are aggressively buying. The analysis of insiders' sentiment of trading Nephros stock suggests that almost all insiders are extremely bullish at this time. Nephros employs about 31 people. The company is managed by 19 executives with a total tenure of roughly 83 years, averaging almost 4.0 years of service per executive, having 1.63 employees per reported executive.
| Daron Evans CEO CEO and President Acting CFO, Director and Member of Audit Committee |
| Andrew Astor CEO CFO, CEO |
Nephros' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2023-12-07 | Robert R Jr. Banks | Acquired 18000 @ 2.2 | View | ||
| 2023-08-14 | Robert R Jr. Banks | Acquired 99 @ 1.5 | View |
Monitoring Nephros' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Nephros |
Nephros' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Nephros' future performance. Based on our forecasts, it is anticipated that Nephros will maintain a workforce of under 30 employees by May 2024.Nephros Management Team Effectiveness
The company has return on total asset (ROA) of (0.0871) % which means that it has lost $0.0871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1827) %, meaning that it created substantial loss on money invested by shareholders. Nephros' management efficiency ratios could be used to measure how well Nephros manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.16. The current Return On Capital Employed is estimated to decrease to -0.17. As of now, Nephros' Asset Turnover is increasing as compared to previous years.The Nephros' current Common Stock Shares Outstanding is estimated to increase to about 10.9 M, while Net Loss is forecasted to increase to (6.3 M).
Nephros Workforce Comparison
Nephros is considered to be number one stock in number of employees category among related companies. The total workforce of Consumer Discretionary industry is now estimated at about 167,470. Nephros adds roughly 31.0 in number of employees claiming only tiny portion of stocks in Consumer Discretionary industry.
The company has Profit Margin (PM) of (0.11) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.2) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.2. Nephros Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nephros insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nephros' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Nephros insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 2.0 | 2 | 1 | 98,463 | 91,463 |
| 2022-03-01 | 0.3333 | 1 | 3 | 14,815 | 36,019 |
| 2021-06-01 | 0.75 | 3 | 4 | 68,889 | 68,476 |
| 2021-03-01 | 4.25 | 17 | 4 | 227,520 | 14,754 |
| 2020-12-01 | 3.0 | 3 | 1 | 169,167 | 103,973 |
| 2020-06-01 | 2.0 | 2 | 1 | 2,732 | 1,732 |
| 2018-09-01 | 1.0 | 1 | 1 | 85,199 | 0.00 |
| 2018-06-01 | 3.0 | 6 | 2 | 232,333 | 73,333 |
| 2015-12-01 | 2.0 | 2 | 1 | 2,825,416 | 2,782,576 |
| 2015-09-01 | 8.0 | 16 | 2 | 24,007,163 | 23,484,200 |
| 2014-06-01 | 1.0 | 1 | 1 | 48,864 | 0.00 |
| 2013-12-01 | 4.0 | 4 | 1 | 119,639 | 0.00 |
| 2011-03-01 | 11.0 | 11 | 1 | 74,563,042 | 0.00 |
| 2009-09-01 | 0.125 | 1 | 8 | 20,000 | 850,600 |
| 2009-03-01 | 0.1429 | 2 | 14 | 100,000 | 433,439 |
| 2008-12-01 | 0.0833 | 1 | 12 | 1,109,365 | 2,620,143 |
| 2008-09-01 | 0.0667 | 1 | 15 | 750,000 | 244,800 |
| 2008-06-01 | 0.1053 | 2 | 19 | 1,499,904 | 2,291,175 |
| 2008-03-01 | 1.0 | 1 | 1 | 481,165 | 481,165 |
| 2007-12-01 | 2.5 | 15 | 6 | 56,571,729 | 1.00 |
| 2006-03-01 | 4.0 | 8 | 2 | 110,000 | 0.00 |
| 2005-06-01 | 9.0 | 9 | 1 | 67,200 | 0.00 |
| 2004-09-01 | 0.3448 | 10 | 29 | 5,869,229 | 16,343,223 |
Nephros Notable Stakeholders
A Nephros stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Nephros often face trade-offs trying to please all of them. Nephros' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Nephros' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Robert Banks | CEO President | Profile | |
| Daron Evans | CEO and President Acting CFO, Director and Member of Audit Committee | Profile | |
| Andrew Astor | CFO, CEO | Profile | |
| Greg Lucas | President Systems | Profile | |
| Malcom Persen | Director | Profile | |
| Thomas Gwydir | Director | Profile | |
| Paul Mieyal | Director | Profile | |
| Alfred Vargas | Director Operations | Profile | |
| Alisa Lask | Director | Profile | |
| Matthew Rosenberg | Director | Profile | |
| Moshe Pinto | Director | Profile | |
| Arthur Amron | Independent Director | Profile | |
| Oliver Spandow | Director | Profile | |
| Vashone Thomas | Regulatory, Quality | Profile | |
| Joleen Turner | VP Devel | Profile | |
| Judy CFA | Chief Officer | Profile | |
| Judy Mazzini | Controller | Profile | |
| MS MBA | Inc Products | Profile | |
| Brianne McGuire | Marketing Brand | Profile |
About Nephros Management Performance
The success or failure of an entity such as Nephros often depends on how effective the management is. Nephros management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Nephros management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Nephros management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.16) | (0.17) | |
| Return On Assets | (0.13) | (0.14) | |
| Return On Equity | (0.19) | (0.20) |
The data published in Nephros' official financial statements usually reflect Nephros' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Nephros. For example, before you start analyzing numbers published by Nephros accountants, it's critical to develop an understanding of what Nephros' liquidity, profitability, and earnings quality are in the context of the Household Durables space in which it operates.
Please note, the presentation of Nephros' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Nephros' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Nephros' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Nephros. Please utilize our Beneish M Score to check the likelihood of Nephros' management manipulating its earnings.
Nephros Workforce Analysis
Traditionally, organizations such as Nephros use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Nephros within its industry.Nephros Manpower Efficiency
Return on Nephros Manpower
| Revenue Per Employee | 459.3K | |
| Revenue Per Executive | 749.4K | |
| Net Loss Per Employee | 50.8K | |
| Net Loss Per Executive | 82.9K | |
| Working Capital Per Employee | 203K | |
| Working Capital Per Executive | 331.2K |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Nephros Stock analysis
When running Nephros' price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Nephros' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.371 | Quarterly Revenue Growth 0.272 | Return On Assets (0.09) | Return On Equity (0.18) |
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nephros is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.